Insight Molecular Diagnostics Inc. (IMDX) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Insight Molecular Diagnostics Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMDX
Insight Molecular Diagnostics Inc.
$3.47HealthcareDelayed quote: Oct 6, 2026, 2:39 PM EDT
MXCT
MaxCyte, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 2:39 PM EDT
Total return — IMDX vs MXCT
growth of $100 · dividends reinvested · last 5yIMDX -96.6% (-49.0%/yr)MXCT -93.6% (-42.4%/yr)MXCT compounded faster over this window
IMDX MXCT
IMDX vs MXCT: by the numbers
- •MXCT is the larger company ($114M vs $112M market cap).
- •Both run net losses; MXCT's is the smaller (-114.77% vs -2955.63% net margin).
- •IMDX grew revenue faster over the past five years (27.24% vs 1.46% CAGR).
Metrics side by side
Valuation
| Metric | IMDX | MXCT |
|---|---|---|
| P/S ratio | 67.00 | 3.67 |
| P/B ratio | N/A | 0.72 |
Profitability
| Metric | IMDX | MXCT |
|---|---|---|
| Gross margin | 11.17% | 79.43% |
| Operating margin | -754.08% | -137.12% |
| Net margin | -2955.63% | -114.77% |
| ROE | N/A | -22.45% |
| ROIC | -223.06% | -19.83% |
Growth (annualized)
| Metric | IMDX | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | 27.24% | 1.46% |
| Total return CAGR (5Y) | -44.39% | -37.32% |
Frequently asked
- Which has grown faster, IMDX or MXCT?
- Over the past five years, IMDX grew revenue faster — IMDX at a 27.24% CAGR versus MXCT at 1.46%.
- How have IMDX and MXCT total returns compared?
- Over the past 5 years, IMDX delivered -44.39% and MXCT delivered -37.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Insight Molecular Diagnostics ROEMaxCyte ROEInsight Molecular Diagnostics operating marginMaxCyte operating marginInsight Molecular Diagnostics revenue growthMaxCyte revenue growthInsight Molecular Diagnostics free cash flowMaxCyte free cash flow
Insight Molecular Diagnostics & MaxCyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.